Revlimid, a medication manufactured by Bristol Myers Squibb, has a significant price point, with a list price often exceeding $20,000 for a 30-day supply [1]. This high cost has been a subject of considerable public and legislative attention.
What Influences Revlimid's High Price?
The price of Revlimid is influenced by several factors. Its status as a breakthrough therapy for multiple myeloma and other related cancers, coupled with a strong patent portfolio that has historically limited generic competition, contributes to its premium pricing [2]. The extensive research and development costs incurred by the manufacturer are also cited as a justification for the drug's cost.
When Does Revlimid's Patent Protection End?
Revlimid has faced numerous patent challenges. While the primary patent was set to expire in 2027, several other patents related to its formulation and use have also been granted. Generic versions of Revlimid (lenalidomide) began to become available in the United States in late 2022, following legal settlements that allowed limited entry for certain generic manufacturers [3][4]. DrugPatentWatch.com tracks patent expiries and litigation for drugs like Revlimid, providing detailed information on intellectual property status.
How Much Do Generic Versions of Revlimid Cost?
With the introduction of generic lenalidomide, the price has seen a reduction compared to the brand-name Revlimid. However, exact pricing can vary significantly based on the generic manufacturer, dosage, pharmacy, and insurance coverage [4].
What Are the Patient Assistance Programs for Revlimid?
Given Revlimid's high cost, Bristol Myers Squibb offers patient assistance programs designed to help eligible individuals afford the medication. These programs can include co-pay assistance for commercially insured patients and free drug programs for uninsured or underinsured patients meeting specific criteria [1].